SMMT

Summit Therapeutics Inc

16.20

Oct 21 • 6:58 AM ET +0.11 (0.68%)

Healthcare Biotechnology USA Large NASD

Today, 6:15 AMSummit Therapeutics, ECOG-ACRIN to run registrational Phase II/III trial of ivonescimab in first-line biliary tract cancer

Peers: BNTX CBIO GMAB ONC EXEL MRK PFE IOVA BMY CMPX

| Held by: VTI VB XBI VBR VXF IBB IWP IWR IWF SCHM

Scroll to Statements

Index	-
Market Cap	12.92B
Enterprise Value	12.25B
Income	-856.09M
Sales	0.00M
Book/sh	0.79
Cash/sh	0.87
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	265
IPO	Mar 05, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	20.40
P/C	18.70
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	6.96
Current Ratio	6.96
Debt/Eq	0.03
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-1.12
EPS next Y	-1.13
EPS next Q	-0.28
EPS this Y	19.42%
EPS next Y	2.38%
EPS next 5Y	21.71%
EPS past 3/5Y	-52.45% -13.76%
Sales past 3/5Y	- -
EPS Y/Y TTM	-11.10%
Sales Y/Y TTM	-
EPS Q/Q	63.61%
Sales Q/Q	-
Earnings	Jul 23 AMC
EPS/Sales Surpr.	-2.04% -

Insider Own	80.92%
Insider Trans	1.23%
Inst Own	17.16%
Inst Trans	12.42%
ROA	-159.09%
ROE	-192.50%
ROIC	-132.35%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.96%
SMA50	2.80%
SMA200	-0.45%
Trades

Shs Outstand	793.12M
Shs Float	152.24M
Short Float	27.03%
Short Ratio	6.77
Short Interest	41.16M
52W High	29.23 -44.58%
52W Low	12.07 34.22%
Volatility	5.24% 6.33%
ATR (14)	0.97
RSI (14)	50.05
Beta	-1.53
Rel Volume	0.03
Avg Volume	6.08M
Volume	8,104

Perf Week	7.07%
Perf Month	-5.37%
Perf Quarter	8.14%
Perf Half Y	-34.09%
Perf YTD	-7.38%
Perf Year	-13.55%
Perf 3Y	775.68%
Perf 5Y	220.16%
Perf 10Y	34.22%
Recom	1.67
Target Price	30.06
Prev Close	16.09
Price	16.20
Change %	0.68%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-09-26	Upgrade	Jefferies	Hold → Buy	$25
Aug-25-26	Upgrade	Bernstein	Underperform → Mkt Perform	$11.90
Aug-12-26	Upgrade	Leerink Partners	Underperform → Market Perform	$13
May-22-26	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-08-26	Initiated	Stifel	Buy	$45
Mar-16-26	Downgrade	Jefferies	Buy → Hold	$15
Dec-17-25	Upgrade	Barclays	Underweight → Equal Weight	$18
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Sep-17-25	Initiated	Barclays	Underweight	$13
Sep-04-25	Initiated	Guggenheim	Buy	$40
Aug-19-25	Initiated	Piper Sandler	Neutral	$21
Jul-01-25	Initiated	UBS	Buy	$30
Jun-11-25	Initiated	Leerink Partners	Underperform	$12
Mar-26-25	Upgrade	Citigroup	Neutral → Buy	$23 → $35
Mar-21-25	Initiated	Cantor Fitzgerald	Overweight
Mar-12-25	Initiated	Evercore ISI	Outperform	$30
Feb-28-25	Initiated	Goldman	Buy	$42
Jan-08-25	Initiated	Truist	Buy	$35
Dec-11-24	Initiated	Wells Fargo	Overweight	$30
Dec-06-24	Initiated	Jefferies	Buy	$31

Show Previous Ratings

Today 06:05AM	Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer (Business Wire)
Oct-19-26 07:00AM	Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma (Business Wire) +6.43%
Oct-06-26 10:01PM	Goldman Sachs Says China Biotech Is Where Big Pharma Is Shopping Now (BeInCrypto)
07:44AM	AstraZeneca CEO Pascal Soriot on Summit ivonescimab combos (Quartz)
Oct-05-26 07:00AM	AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics (Business Wire)
01:58PM	Loading…
Oct-02-26 01:58PM	AstraZeneca Stocks Moves Lower as Datroway Combination Enters Phase 3 (GuruFocus.com)
10:30AM	AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact (Pharmaceutical Technology)
08:38AM	Summit Teams Up With Daiichi Sankyo, AstraZeneca For Cancer Therapy Trial CEO Calls It An Important Expansion (Stocktwits)
02:30AM	Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway (Business Wire)
02:30AM	Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway in Combination with Ivonescimab Across Multiple Tumor Types (Business Wire)
Oct-01-26 07:57PM	AstraZeneca Stocks Drops as $2 Billion Buys an Oncology Option (GuruFocus.com)
Sep-29-26 01:17PM	AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology (GuruFocus.com) +5.88%
12:07PM	Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment (GuruFocus.com)
08:49AM	AstraZeneca invests $2B in Summit, gaining seat at the table for PD-1/VEGF drug push (BioPharma Dive)
08:30AM	AstraZenecas $2 billion Summit stake wins backing from UBS and Jefferies (Proactive)
07:39AM	Loading…
07:39AM	Premarket movers: FICO sinks while Summit, AAR and CarMax rise (Investing.com)
06:24AM	Summit Therapeutics Shares Rise 22% After $2 Billion AstraZeneca Investment (InvestorsHub)
05:58AM	AMD, Nvidia, Navitas, Summit Therapeutics, Fair Isaac, and More Stocks That Explain Today's Market (Barrons.com)
02:32AM	AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal (Proactive)
Sep-28-26 07:35PM	SMMT Stock Soars After-Hours: Did AstraZeneca Just End Summits Cash Scare? (Stocktwits)
07:28PM	Summit Shares Surge on $2 Billion AstraZeneca Investment (The Wall Street Journal)
06:27PM	Summit Therapeutics Stock Surges After AstraZeneca Reveals $2 Billion Investment (Barrons.com)
06:08PM	Summit shares surge after-hours on $2 billion AstraZeneca equity deal (Investing.com)
05:30PM	AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics (Business Wire)
Sep-22-26 06:00AM	HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026 (Business Wire)
Sep-15-26 06:00AM	Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients (Business Wire) -5.54%
Sep-14-26 12:41PM	Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results (BioPharma Dive)
Sep-13-26 07:00AM	Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China (Business Wire)
Sep-09-26 10:07AM	Summit Therapeutics shares gain after Jefferies upgrades stock to Buy (InvestorsHub)
09:51AM	Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls (The Fly)
12:00PM	Loading…
Sep-03-26 12:00PM	Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug (Barrons.com) +17.33%
Sep-02-26 05:41PM	Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China (Business Wire)
Aug-26-26 01:51PM	Summits Global Lung Cancer Trials Gain Credibility After Akesos Phase 3 Data, Says Guggenheim (Stocktwits) +6.51%
08:37AM	Summit Therapeutics shares rise after partner reports positive Phase III cancer trial results (InvestorsHub)
07:29AM	Akeso logs Phase III success in second tumour type for ivonescimab (Clinical Trials Arena)
Aug-25-26 06:00PM	Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China (Business Wire)
07:00AM	Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology (Business Wire)
06:51AM	Summit Therapeutics Shares Rise After Bernstein SocGen Upgrade (InvestorsHub)
Aug-12-26 09:22AM	Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer (Business Wire)
Aug-05-26 07:00AM	Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer (Business Wire)
Jul-24-26 01:01AM	Summit Therapeutics Inc (SMMT) Q2 2026 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com) -8.81%
Jul-23-26 04:05PM	Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 (Business Wire)
Jul-22-26 04:30PM	Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer (Business Wire)
02:57PM	SMMT Stock Gains After Summit Reports Strong Lung Cancer Survival Results Investors Await Q2 Earnings (Stocktwits)
08:24AM	Summit Therapeutics shares advance after updated Phase III cancer trial results (NASDAQ:SMMT) (InvestorsHub)
06:30AM	Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study (Business Wire)
05:33AM	Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study (BioPharma Dive)
Jul-20-26 02:00AM	What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment. (Barrons.com)
Jul-16-26 08:00AM	Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026 (Business Wire) -8.69%
Jul-15-26 05:18AM	J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals (BioPharma Dive)
Jul-14-26 07:00AM	Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc. (Business Wire)
Jun-23-26 10:19AM	Summit Therapeutics finance chief tops list of public CFO pay in 2025 (CFO.com)
Jun-10-26 07:19AM	Why Is SMMT Stock Tumbling Today? (Stocktwits) -8.68%
Jun-09-26 04:47PM	Summit Therapeutics Announces Proposed Public Offering of Common Stock (Business Wire)
Jun-04-26 04:30PM	Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference (Business Wire)
04:55AM	Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? (Pharma Voice)
Jun-02-26 08:44PM	ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC (Pharmaceutical Technology) -5.41%
Jun-01-26 08:06AM	An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed. (MarketWatch) -10.43%
12:25AM	SMMT Stock Surges Overnight: Cancer Drug Survival Win Raises The Bar As PFE, BMY, MRK Chase Keytruda's Successor (Stocktwits)
May-31-26 09:06AM	Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China (Business Wire)
May-30-26 08:00AM	Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026 (Business Wire)
May-28-26 06:33PM	Akari Therapeutics Highlights 1st ASCO Abstract Acceptance (IPO-Edge.com)
12:53PM	VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC (Exec Edge)
May-22-26 09:38AM	Texas Instruments, Generac upgraded: Wall Street's top analyst calls (The Fly)
07:46AM	ASCO26: 5 data snapshots ahead of the years biggest cancer drug meeting (BioPharma Dive)
May-18-26 02:22PM	B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic (PR Newswire) -5.04%
May-01-26 08:28AM	Summits self-inflicted stumble; Esperions take-private deal (BioPharma Dive) -24.91%
Apr-30-26 04:32PM	Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 (Business Wire)
Mar-27-26 08:15AM	Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 (Business Wire)
Mar-03-26 02:21AM	Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment (Insider Monkey) -6.67%
Mar-02-26 02:56AM	Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab (Insider Monkey)
Feb-26-26 06:45PM	Summit Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
09:38AM	RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View (Zacks)
Feb-24-26 08:02PM	Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
11:31AM	SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus (Zacks)
08:30AM	Summit Therapeutics Inc. Q4 2025 Earnings Call Summary (Moby)
Feb-23-26 08:17PM	Summit Therapeutics Q4 Earnings Call Highlights (MarketBeat)
04:05PM	Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 (Business Wire)
Feb-22-26 07:47AM	Nvidia earnings, SCOTUS tariff fallout, geopolitical tensions rise: What to watch this week (Yahoo Finance)
Feb-17-26 05:05PM	Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 (Business Wire)
Feb-16-26 12:24PM	Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough (Insider Monkey)
Feb-13-26 10:49AM	MRK Up More Than 7% on Improved Long-Term Prospects: Still a Sell? (Zacks)
Feb-12-26 06:54AM	Is Summit Therapeutics Inc. (SMMT) One of the Most Oversold NASDAQ Stocks to Invest In? (Insider Monkey)
Feb-06-26 08:00AM	China Biotech Lights Up. U.S. Stocks Prepare For A New Powerhouse. (Investor's Business Daily) +8.23%
Feb-05-26 07:22AM	FDA Accepts Summit Therapeutics' (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data (Insider Monkey)
Jan-31-26 07:13PM	2 Stocks That Could Soar This Year (Motley Fool)
Jan-30-26 04:30PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.97%
10:24AM	FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug (Zacks)
07:50AM	Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings (Zacks)
Jan-29-26 12:28PM	FDA Accepts Summit's Lung Cancer Drug Application, Review Underway (Benzinga)
07:30AM	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy (Business Wire)
05:20AM	Moderna holds a garage sale; Roche defends obesity drug data (BioPharma Dive)
Jan-28-26 06:57AM	Encouraging Guidance on Clinical Program Makes Summit Therapeutics (SMMT) Look Attractive (Insider Monkey)
Jan-18-26 12:31PM	Trip.com, Regencell Bioscience, And Atlassian Are Among Top 10 Large Cap Losers Last Week (Jan. 12-Jan. 16): Are the Others in Your Portfolio? (Benzinga)
Jan-15-26 10:20PM	Akeso Confident of Cancer Drug's FDA Approval Odds (Bloomberg)
Jan-12-26 12:43PM	Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? (Benzinga) -13.41%
12:05PM	2 Biotech Stocks That Could Soar This Year (Motley Fool)
06:15AM	Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC) (Business Wire)
06:00AM	Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC (Business Wire)
Jan-09-26 08:16PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zanganeh Mahkam	Co-Chief Executive Officer	Jun 12 '26	Buy	13.12	3,810,000	49,987,200	573,883,879	Jun 12 02:35 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	Jun 12 '26	Buy	13.12	3,810,000	49,987,200	573,883,879	Jun 12 12:28 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	Jun 04 '26	Buy	14.60	100,000	1,460,000	25,824,474	Jun 04 06:08 PM
Zanganeh Mahkam	Co-Chief Executive Officer	Jun 04 '26	Buy	14.60	100,000	1,460,000	25,824,474	Jun 04 05:45 PM
Soni Manmeet Singh	COO and CFO	Jun 04 '26	Buy	14.45	50,000	722,250	3,123,603	Jun 04 04:40 PM

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Co-CEO & Executive ChairmanMr. Robert W. Duggan

M.B.A.Dr. Mahkam Zanganeh D.D.S.

COOMr. Manmeet Singh Soni CPA

FRS CBEProf. Kay Elizabeth Davies DBE

Chief Accounting Officer & Head of FinanceMr. Bhaskar Anand

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SMMT

Summit Therapeutics Inc

Upgrade your Finviz experience